Analysts’ Weekly Ratings Changes for First Tracks Biotherapeutics (TRAX)

First Tracks Biotherapeutics (NASDAQ: TRAX) has recently received a number of price target changes and ratings updates:

• 5/4/2026 – First Tracks Biotherapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $54.00 price target on the stock.
• 5/2/2026 – First Tracks Biotherapeutics was upgraded by Wall Street Zen to “hold”.
• 4/28/2026 – First Tracks Biotherapeutics is now covered by HC Wainwright. They set a “buy” rating and a $30.00 price target on the stock.
• 4/28/2026 – First Tracks Biotherapeutics was upgraded by HC Wainwright to “strong-buy”. They now have a $30.00 price target on the stock.
• 4/27/2026 – First Tracks Biotherapeutics was upgraded by Zacks Research to “hold”.
• 4/24/2026 – First Tracks Biotherapeutics is now covered by Wedbush. They set an “outperform” rating and a $30.00 price target on the stock.
• 4/24/2026 – First Tracks Biotherapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $46.00 price target on the stock.
• 4/23/2026 – First Tracks Biotherapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $31.00 price target on the stock.
• 4/22/2026 – First Tracks Biotherapeutics is now covered by Barclays PLC. They set an “overweight” rating and a $40.00 price target on the stock.
• 4/21/2026 – First Tracks Biotherapeutics is now covered by UBS Group AG. They set a “buy” rating and a $45.00 price target on the stock.